Bacillus Calmette-Guérin versus Gemcitabine for Intravesical Therapy in High-Risk Superficial Bladder Cancer: A Randomised Prospective Study

Publisher： Karger

E-ISSN： 1423-0399|84|1|23-27

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.84, Iss.1, 2010-02, pp. : 23-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intravesical Bacillus Calmette-Guérin Therapy for T1 Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 80, Iss. 1, 2008-01 ,pp. : 74-79

Karger

Access to resources Recommend Favorite

Cytological Changes Induced by Intravesical Bacillus Calmette-Guérin Therapy for Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 2, 2000-05 ,pp. : 74-81

Karger

Access to resources Recommend Favorite

Pharmacokinetic Study of Intravesical Gemcitabine in Carcinoma in situ of the Bladder Refractory to Bacillus Calmette-Guérin Therapy

By  

Urologia Internationalis, Vol. 75, Iss. 4, 2005-12 ,pp. : 309-313

Karger

Access to resources Recommend Favorite

Urinary Fibronectin Levels in Patients Treated with Intravesical Bacillus Calmette-Guérin for Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 4, 2006-01 ,pp. : 198-201

Karger

Access to resources Recommend Favorite

Intravesical Combined Chemoimmunotherapy with Epirubicin and Bacillus Calmette-Guérin Is Not Indicated for Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 67, Iss. 4, 2001-12 ,pp. : 289-292

Karger

Access to resources Recommend Favorite